(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 12.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Bioage Labs's earnings in 2026 is -$89,930,000.On average, 10 Wall Street analysts forecast BIOA's earnings for 2026 to be -$121,293,730, with the lowest BIOA earnings forecast at -$136,354,316, and the highest BIOA earnings forecast at -$106,419,845. On average, 10 Wall Street analysts forecast BIOA's earnings for 2027 to be -$118,568,777, with the lowest BIOA earnings forecast at -$161,447,885, and the highest BIOA earnings forecast at -$77,481,115.
In 2028, BIOA is forecast to generate -$135,385,247 in earnings, with the lowest earnings forecast at -$170,942,989 and the highest earnings forecast at -$114,354,658.